Encompass Health (NYSE:EHC) CEO Mark Tarr Sells 173,148 Shares of Stock

Encompass Health Corporation (NYSE:EHC) CEO Mark Tarr sold 173,148 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.47, for a total value of $21,724,879.56. Following the completion of the sale, the chief executive officer directly owned 267,814 shares of the company’s stock, valued at approximately $33,602,622.58. This trade represents a 39.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Encompass Health Price Performance

EHC opened at $124.84 on Wednesday. The stock’s 50 day simple moving average is $107.84 and its 200 day simple moving average is $104.99. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.17. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 2.55 and a beta of 0.72.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, analysts predict that Encompass Health Corporation will post 6.08 earnings per share for the current year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Thursday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s dividend payout ratio is currently 12.38%.

Analyst Upgrades and Downgrades

EHC has been the topic of a number of analyst reports. Wall Street Zen cut shares of Encompass Health from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group raised their target price on Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen upped their price target on Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Monday. Truist Financial increased their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Weiss Ratings lowered Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Encompass Health has a consensus rating of “Moderate Buy” and a consensus target price of $148.71.

Hedge Funds Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently modified their holdings of EHC. Callan Family Office LLC bought a new position in Encompass Health in the second quarter worth about $416,000. Heartland Advisors Inc. purchased a new position in shares of Encompass Health during the 2nd quarter worth approximately $424,000. C M Bidwell & Associates Ltd. bought a new position in shares of Encompass Health in the 2nd quarter worth approximately $57,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Encompass Health in the 2nd quarter valued at approximately $39,000. Finally, Allworth Financial LP bought a new stake in shares of Encompass Health during the second quarter valued at approximately $125,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.